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Abstract (max.250w) 1 
O6-methylguanine DNA methyltransferase (MGMT) promoter methylation is a 2 
predictive biomarker for benefit from alkylating chemotherapy, specifically 3 
temozolomide (TMZ), in glioblastoma, the most common malignant intrinsic brain 4 
tumor. Glioma-initiating cells (GIC) with stem-like properties have been associated 5 
with resistance to therapy and progression. We assessed the levels of MGMT mRNA 6 
and MGMT protein by real-time PCR and immunoblot and evaluated the impact of 7 
MGMT on TMZ sensitivity in clonogenicity assays in GIC sphere cultures (S) or 8 
differentiated adherent monolayer cultures (M). Similar experiments were performed 9 
in long-term glioma cell lines (LTC). Nuclear factor kappa B (NF-κB) signalling was 10 
assessed by reporter assay and immunoblot. Compared to M cells, S cells expressed 11 
higher levels of MGMT. Differentiation of GIC induced by S-to-M transition resulted in 12 
a gradual loss of MGMT expression and increased TMZ sensitivity. This 13 
transcriptional regulation of MGMT was restricted to cell lines without MGMT 14 
promoter methylation and was not coupled to any specific neurobasal (NB) stem cell 15 
medium supplement or loss of cell adhesion. Expression levels of p50/p65 subunits 16 
of NF-κB, a transcriptional regulator of MGMT, were increased in S cells. Inhibition of 17 
NF-κB by the small molecule inhibitor, BAY 11-7082, or siRNA-mediated gene 18 
silencing, reduced MGMT levels. In summary, alkylator resistance of S cells is mainly 19 
promoted by overexpression of MGMT which results from increased activity of the 20 
NF-κB pathway in this cell culture model of glioma stem-like cells. 21 
 22 
Abbreviations 23 
BMP-4, bone morphogenetic protein-4; CAIX, carbonic anhydrase 9; CIL, cilengitide; 24 
DMEM, Dulbecco`s modified Eagle medium; FGF, fibroblast growth factor; FCS, fetal 25 
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calf serum; GAL, GLPG0187; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 1 
GIC, glioma-initiating cell; ITGA6, Integrin alpha-6 precursor; ITGB1, Integrin beta-1 2 
precursor; KPS, Karnofsky performance score; L1CAM, neural cell adhesion 3 
molecule L1; LTC, long-term cell line; M, monolayer cells or cultures; MGMT, O6-4 
methylguanine DNA methyltransferase; NANOG, homeobox protein nanog; NB, 5 
neurobasal medium; NF-κB, nuclear factor kappa B; OCT4, octamer binding 6 
transcription factor 4; PBS, phosphate-buffered saline; qPCR, quantitative 7 
polymerase chain reaction; RAD, cyclo-(Arg-Ala-Asp-DPhe-Val); RRID, Research 8 
Resource Identifiers; S, sphere cells or cultures; TMZ, temozolomide. 9 
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Glioblastomas, the most malignant primary brain tumors in adults, are characterized 1 
by their infiltrative growth pattern and resistance to radiotherapy and cytotoxic 2 
chemotherapy. Current multimodality treatment approaches include surgery, 3 
radiotherapy and alkylating agent chemotherapy using temozolomide (TMZ) (Weller 4 
et al. 2017); yet, recurrence is inevitable and median survival is still in the range of 5 
12-17 months (Johnson & O'Neill 2012, Gramatzki et al. 2016). Tumors lacking 6 
methylation of the promoter region of the O6-methylguanine-DNA-methyltransferase 7 
(MGMT) gene, which encodes a DNA repair protein, are especially prone to early 8 
progression during standard chemoradiotherapy (Hegi et al. 2005).  9 
Glioma-initiating cells (GIC), also referred to as stem-like glioma cells, are a 10 
subpopulation of cells within a glioma considered to maintain a pool of highly 11 
treatment-resistant cells responsible for treatment failure and progression (Lathia et 12 
al. 2015). The role of MGMT specifically in the GIC compartment has been 13 
addressed in various experimental approaches, but no uniform concept has emerged 14 
(Beier et al. 2008, Blough et al. 2010, Sciuscio et al. 2011). In a panel of ten paired 15 
samples of glioblastomas and their derived sphere cultures, MGMT promoter 16 
methylation was highly enriched in sphere cells, with MGMT protein levels being 17 
accordingly reduced (Sciuscio et al. 2011). Glioma-derived stem cells with sphere 18 
forming capacity have even been suggested as preferential targets of TMZ-induced 19 
tumor cell depletion (Beier et al. 2008). Other groups have shown a heterogeneous 20 
pattern of resistance to TMZ in GIC cultures, with resistant as well as sensitive GIC 21 
displaying heterogeneous MGMT promoter methylation, concluding that its mere 22 
presence does not predict sensitivity to TMZ. Yet, MGMT protein levels correlated 23 
with TMZ sensitivity in this panel of 20 GIC (Blough et al. 2010). In cultures of side 24 
population-derived neurospheres, stem cell properties and MGMT expression were 25 
enriched compared to the bulk population of tumor cells (Bleau et al. 2009). Yet, 26 
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more recently the side population has been proposed to consist essentially of non-1 
neoplastic cells (Golebiewska et al. 2013) which would explain increased MGMT 2 
expression. Here we explore the relationship between the stemness phenotype of 3 
cultured glioma cells and MGMT expression in vitro and link nuclear factor kappa B 4 
(NF-kB) activation with consecutive MGMT induction to stemness and 5 
chemoresistance. 6 
  7 
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Materials and Methods 1 
 2 
Reagents 3 
TMZ was provided by Schering-Plough (Kenilworth, NJ). A stock solution of TMZ at 4 
200 mM was prepared in dimethylsulfoxide (DMSO) and stored at -20°C. Human 5 
MGMT antibody was purchased from Alpha Diagnostics (San Antonio, TX). 6 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (EB07069) 7 
(RRID:AB_2247304) was obtained from Everest Biotech (Oxfordshire, UK). β-Actin 8 
antibody (sc-1616) (RRID:AB_630836) was obtained from Santa Cruz Biotechnology 9 
(Dallas, TX). BAY 11-7082 (Selleckchem, Houston, TX) was prepared as 50 mM 10 
stock solution in DMSO. Cilengitide (EMD121974) was kindly provided by Merck 11 
KGaA (Darmstadt, Germany). GLPG0187 was kindly provided by Galapagos NV 12 
(Mechelen, Belgium). RAD peptide cyclo-Arg-Ala-Asp-DPhe-Val was purchased from 13 
Bachem AG (Bubendorf, Switzerland). Bone morphogenetic protein (BMP)-4 was 14 
from R&D (Minneapolis, MN). O6-benzylguanine (O6-BG) and all other reagents, 15 
unless indicated otherwise, were purchased from Sigma (St. Louis, MO). 16 
 17 
Cell lines 18 
The human glioma-initiating (stem-like) cell lines (GIC) GS-2, GS-5, GS-7, GS-8, GS-19 
9 (Gunther et al. 2008), T-325 (Lemke et al. 2014), ZH-161 and ZH-305 (Silginer et 20 
al. 2016, Stojcheva et al. 2016) were maintained as sphere (S) cultures in 21 
Neurobasal Medium® supplemented with 2% B-27 supplement, 1% GlutaMAX, 20 22 
ng/ml epidermal growth factor (EGF), 20 ng/ml fibroblast growth factor (FGF) and 32 23 
IE/ml heparin. The human glioma cell line T98G (RRID:CVCL_0556) was purchased 24 
from the American Type Culture Collection (Rockville, MD). The glioma cell lines LN-25 
18 (RRID:CVCL_0392) , LN-229 (RRID:CVCL_0393) and LN-308 26 
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(RRID:CVCL_0394) were kindly provided by N. de Tribolet (Lausanne, Switzerland). 1 
LN-18_R cells have been described (Happold et al. 2012). These long-term cell lines 2 
(LTC) were commonly cultured as monolayers (M) in Dulbecco’s modified Eagle 3 
medium (DMEM) containing 10% FCS and 2 mM glutamine from Gibco Life 4 
Technologies (Carlsbad, CA). LN-229_MGMT and LN-229_Neo cells have been 5 
described (Hermisson et al. 2006). In selected experiments the culture conditions 6 
were switched for both GIC and LTC, as outlined below. Cells isolated from freshly 7 
resected human glioblastoma tumor tissue (ZH-464, ZH-456, ZH-419, ZH-496 and 8 
ZH-525) were collected after written informed consent of the patients and approval by 9 
the institutional review board. Briefly, these cells were extracted from tumor tissue by 10 
dissociating tissue with 10 mg/ml collagenase/dispase (Roche, Basel, Switzerland) 11 
and gentle rotation in MACS C-tubes (Miltenyi biotech, Cologne, Germany). Cells 12 
were counted and 20 µl of FcR blocking reagent and 20 µl of CD133 microbeads 13 
(Miltenyi biotech) were added per 107 cells. Cells were incubated for 45 min at 4°C, 14 
passed through a 40 µm cell strainer, and then passed through an LS column placed 15 
in the magnetic field of the MACS separator. The passing CD133-negative population 16 
was passed a second time through a second column to get a purer CD133-negative 17 
population. CD133-positive cells remained in the column and were collected 18 
separately by forceful washing. 19 
 20 
Quantitative PCR 21 
Total RNA was prepared using the NucleoSpin System (Macherey-Nagel AG, 22 
Oensingen SO, Switzerland) and transcribed into cDNA. For real-time (quantitative) 23 
qPCR, cDNA amplification was monitored using SYBRGreen chemistry on the 7300 24 
Real time PCR System (Applied Biosystems, Zug, Switzerland). The conditions were: 25 
40 cycles, 95°C/15 sec, 60°C/1 min. Data analysis was done using the ΔΔCT method 26 
8 
 
for relative quantification. The following specific primers were used: GAPDH fwd: 5'-1 
CTCTCTGCTCCTCCTGTTCGAC-3', GAPDH rv: 5'-TGAGCGATGTGGCTCGGCT-2 
3'; MGMT fwd: 5'-GTC GTT CAC CAG ACA GGT GTT A-3’; MGMT rv: 5'- ACA GGA 3 
TTG CCT CTC ATT GCT C-3’. CD133 fwd: 5’-TGGATGCAGAACTTGACAACGT-3’; 4 
CD133 rv: 5’-ATACCTGCTACGACAGTCGTGGT-3’; GFAP fwd: 5’-5 
TCTCTCGGAGTATCTGGGAACTG-3’; GFAP rv: 5’-6 
TTCCCTTTCCTGTCTGAGTCTCA-3’; OCT4 fwd: 5’-7 
TCTCCCATGCATTCAAACTGAG-3’; OCT4 rv: 5’-CCTTTGTGTTCCCAATTCCTTC-8 
3’; MUSASHI fwd: 5’-CCAATGGGTACCACTGAAGC-3’; MUSASHI rv: 5’-9 
ACTCGTGGTCCTCAGTCAGC-3’; TUBB3 fwd: 5’-GCAACTACGTGGGCGACT-3’; 10 
TUBB3 rev: 5’-CGAGGCACGTACTTGTGAGA-3’; OLIG2 fwd: 5’-11 
AGCTCCTCAAATCGCATCC-3’; OLIG2 rv: 5’-ATAGTCGTCGCAGCTTTCG-3’. For 12 
single cell quantitative real-time PCR, human glioblastoma samples were dissociated 13 
with papain (Worthington, Lakewood, NJ) and leukocytes were depleted by anti-14 
human CD45–conjugated microbeads (Miltenyi Biotec, Bergisch Gladbach, 15 
Germany) using MACS LD columns (Miltenyi Biotec). Single cell qPCR was 16 
performed at the Genomics Facility Basel, Switzerland. C1 System (Fludigim, San 17 
Francisco, CA) was used to prepare single-cells for mRNA isolation, cDNA synthesis 18 
and pre-amplification. BioMark HD system was used for RT-PCR analysis of the pre-19 
amplification products (Papa et al. 2017). The following primers were used: SOX-4 20 
(forward 5'-GGTCTCTAGTTCTTGCACGCT-3', reverse 5'- 21 
CTGCAAGAAGGGAGCTGGTAA-3'); SOX-2 (forward 5'-CACACTGCCCCTCTCAC-22 
3'; reverse  5'-TCCATGCTGTTTCTTACTCTCC-3'); MUSASHI (forward 5'-23 
CCAATGGGTACCACTGAAGC -3', reverse 5'-ACTCGTGGTCCTCAGTCAGC -3'); 24 
CD133 (forward 5'- TGGATGCAGAACTTGACAACGT -3', reverse 5'-25 
ATACCTGCTACGACAGTCGTGGT-3'); OCT4 (forward 5'-26 
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CGAGAAGGATGTGGTCCGAG-3', reverse 5'-TGTGCATAGTCGCTGCTTGA-3');  1 
NANOG (forward 5'-GAAATACCTCAGCCTCCAGC-3', reverse  5'-2 
GCGTCACACCATTGCTATTC-3'); Nestin (forward  5'-GGCTGCGGGCTACTGAAA-3 
3', reverse 5'-CTGAGCGATCTGGCTCTGTAG-3'); ITGB1 (forward 5'-4 
AGCCTGTTTACAAGGAGCTGAA-3', reverse 5'-CGCCTTCTGACAATTTGCCG-3'); 5 
L1CAM (forward 5’- CCCCAGGTCACTATCGGCTA -3’, reverse 5’- 6 
GACTGCCCTCCCTCCAGTA -3’); ITGA6 (forward 5'-7 
TCAACAAGGATGGGTGGCAA-3', reverse 5'-TCTGCCTTGCTGGTTCATGT-3') 8 
 9 
Single-cell gene expression analysis correlation experiments 10 
Single-cell gene expression analysis has been described (Stahlberg et al. 2013). Low 11 
quality cells that did not express the housekeeping genes ARF-1 or ARF-1 were 12 
discarded; 481 cells from 6 patients were included in the analyses. Cq values were 13 
converted to expression levels using the equation Log2Ex = Cq LOD (Limit of Detection) – Cq 14 
with a LOD Cq of 25 and data was transformed using asinh transformation. Pearson`s 15 
correlation coefficients were computed using the corrplot R package version 0.77 and 16 
Bonferroni correction was applied to adjust for multiple hypothesis testing. 17 
Scatterplots of significant correlations were plotted using the ggpubr R package 18 
version 0.1.2. 19 
 20 
Spherogenicity and clonogenicity assays 21 
S cells were seeded at 500 cells per well of 96-well plates in neurobasal (NB) 22 
medium, treated 24 h later as indicated, and consecutively maintained in NB medium. 23 
For adherent M cultures, clonogenic assays were performed by seeding 100 cells 24 
(LN-229) or 300 cells (all other LTC or M cells) per well in 96-well plates and allowed 25 
to adhere overnight. The cells were exposed to TMZ at the indicated concentrations 26 
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for 24 h in serum-free medium, followed by an observation period for 7-14 days in the 1 
same medium. In the experiments involving O6-BG, the cells were pretreated with O6-2 
BG or DMSO control for 2 h prior to TMZ application. Cell density was assessed by 3 
MTT assay for S conditions and by crystal violet staining for M conditions. 4 
Representative studies confirmed that the data obtained like that correspond well to 5 
data based on actual counts of spheres or colonies. 6 
 7 
Immunoblot analysis 8 
Cells treated as indicated were lysed on ice in radioimmunoprecipitation assay 9 
(RIPA) lysis buffer (150 mM NaCl, 25 mM Tris-HCl, pH 7.5, 1% Nonidet P-40, 1% 10 
sodium deoxycholate, 0.1% SDS, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium 11 
fluoride, 1 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 μg/ml 12 
leupeptin, 1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid 13 
(EGTA) supplemented with 1x complete inhibitor mix (Roche Diagnostics, Grenzach-14 
Wyhlen, Germany). Pre-cleared cell lysates, mixed and boiled with Laemmli buffer 15 
containing β-mercaptoethanol, were resolved by sodium dodecyl sulfate 16 
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose 17 
membranes (GE Healthcare; Little Chalfont, Buckinghamshire, UK). After blocking in 18 
Tris-buffered saline containing 5% skim milk and 0.05% Tween 20, the blots were 19 
incubated overnight at 4°C with primary antibodies and 1 h at room temperature for 20 
secondary antibodies. Visualization of protein bands was done using horseradish 21 
peroxidase-coupled secondary antibodies (Santa Cruz Biotechnology, Dallas, TX) 22 
and enhanced chemiluminescence (Pierce / Thermo Fisher, Madison, WI). 23 
 24 
Reporter assay 25 
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Cells were either transfected by electroporation directly (for S cells) or by 1 
Lipofectamine 2000 reagent 24 h after seeding to a 96-well plate with 20,000 2 
cells/well) (for M cells), with 200 ng of pNF-κB -Luc plasmid containing a firefly 3 
luciferase gene designed to detect NF-κB  signalling activity, together with 20 ng of 4 
the control renilla plasmid pRL-CMV (Hermisson & Weller 2003). GIC were seeded at 5 
a density of 50,000 cells/well in 96-well plates after transfection. Further treatment 6 
was performed 18 h later, and cells were lysed 6 h post-treatment and luciferase 7 
activity was measured.  8 
 9 
Transient transfection 10 
GIC were dissociated using Accutase cell detachment solution (PAA Laboratories, 11 
Pasching, Austria), and 2x106 cells were transfected using the Neon Transfection 12 
System electroporation device and kit (Invitrogen, Life Technologies) with 100 nM 13 
specific or control. Hereafter, cells were allowed to recover for a day under 14 
neurobasal conditions, and seeded for either survival assays or protein lysate 15 
isolation as described above. 16 
 17 
Proliferation assays 18 
Cells were seeded at a density of 1x105 cells/well in a 96-well plate with 6 well 19 
replicates per time point, and left to grow for the indicated time points. Analysis was 20 
done by MTT assay as described above, and normalized to baseline time point. 21 
 22 
Flow cytometry 23 
For cell cycle analysis, GIC and LTC were harvested, fixed and washed with PBS. 24 
Hereafter, RNA was digested with RNase A (Carl Roth AG, Karlsruhe, Germany), 25 
DNA stained with propidium iodide (PI) (50 ug/ml) and fluorescence was recorded 26 
12 
 
with BD FACSVerse flow cytometer (BD, Heidelberg, Germany). For AnnexinV/PI 1 
flow cytometry, cells were incubated with FITC-labeled AnxV-fluorescin 2 
isothiocyanate and PI for 20 min. Fluorescence was recorded in with a BD 3 
FACSVerse flow cytometer. PI-positive (necrotic) or AnxV-positive (apoptotic) cells or 4 
double positive were counted as dead. 5 
 6 
Statistical analyses 7 
Data are representative of experiments independently performed three times with 8 
similar results unless indicated otherwise with the exception of the freshly resected 9 
tumor tissue cell-based experiments. Viability and proliferation studies were 10 
performed using triplicate wells. Where indicated, analysis of significance was 11 
performed using the two-tailed Student’s t-test. Correlation analysis was done by 12 
Spearman test. No randomization or blinding was performed in this study. Study was 13 
not pre-registered. 14 
 15 
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Results 1 
 2 
Sphere cultures of GIC are more resistant to TMZ than adherent cultures 3 
GIC are considered to promote treatment resistance in glioblastoma and to retain an 4 
expression signature related to stemness that is gradually lost when multi-lineage 5 
differentiation and adherent monolayer growth are induced by exposure to FCS-6 
containing medium (Fig. 1A,B; Supplementary Fig 1A) (Günter et al. 2008, Happold 7 
et al. 2014) . However, we noted that merely shifting of GIC cells from S to M 8 
conditions was associated with greatly enhanced sensitivity to TMZ (Fig. 1C, D). The 9 
EC50 values were shifted up to 10-fold in all GIC except for T-325 and GS-9. In ZH-10 
305, the effect was even reversed (Fig. 1E). Limiting dilution assays were performed 11 
to further characterize TMZ sensitivity of S cells to TMZ as function of cell density 12 
(Supplementary Fig. 1B). No major changes in cell cycle distribution or proliferation 13 
rate were seen between S and M cells (Fig. 1F,G). Moreover, AnxV/PI flow cytometry 14 
did not confirm relevant cell death after exposure to TMZ at clinically relevant 15 
concentrations (Supplementary Fig. 1C). 16 
 17 
High MGMT expression confers TMZ resistance in S cultures 18 
We next investigated whether the loss of resistance to TMZ induced by switching 19 
from S to M culture conditions was associated with changes in MGMT expression. 20 
While most M cultures exhibited only minor decreases in MGMT mRNA expression 21 
levels compared with S cultures (Fig. 2A), we found consistent reduction of MGMT 22 
protein levels in M cultures (Fig. 2B). GS-9 and ZH-305, which did not show 23 
decreased EC50 values when switched to M conditions, did not express MGMT either 24 
under S or M conditions. There was strong correlation between MGMT mRNA levels 25 
determined by qPCR and TMZ sensitivity defined by EC50 values in clonogenicity 26 
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assays (r=0.79, p=0.0003) (Fig. 2C). To confirm that the changes in MGMT levels are 1 
responsible for the sensitization to TMZ during the S→M transition, we pre-exposed 2 
the cells to the MGMT pseudosubstrate inhibitor, O6-BG, for 2 h before TMZ 3 
exposure. Consumption of MGMT levels by O6-BG within 72 h was verified by 4 
immunoblot analysis. Indeed, pre-exposure to O6-BG shifted the sensitivity of S 5 
cultures to TMZ to the range of M cultures (for GS-2) or lower (for GS-5) in 6 
clonogenic survival assays (Fig. 2D).  7 
 8 
MGMT expression correlates with expression of stemness markers  9 
Single cell gene expression analysis performed from freshly resected glioma tissue 10 
confirmed positive correlation of MGMT with various stem cell markers, although not 11 
Musashi (Fig. 3A). Additionally, to confirm differential MGMT expression ex vivo, we 12 
investigated MGMT expression in isolated CD133-positive cells, considered stem-13 
like, versus CD133-negative sorted cells, from freshly resected tumor tissues of five 14 
glioblastoma patients. MGMT mRNA levels were increased at least 2-fold in CD133+ 15 
cells in all patients (Fig. 3B). Conversely, induction of differentiation by bone 16 
morphogenetic protein(BMP)-4 decreased MGMT protein levels in 3 out of 4 S cell 17 
lines (Fig. 3C), as well as CD133 mRNA expression in 3 out of 4 cell lines except for 18 
a reversed effect in T-325, while increasing GFAP mRNA expression (Fig. 3D). 19 
 20 
Impact of culture conditions on MGMT expression in glioma cells 21 
To better understand the regulation of MGMT expression in S versus M cells, we 22 
studied the time course of MGMT loss upon S→M transition in more detail. The 23 
switch of GS-2 and GS-5 S to M conditions led to a rapid drop of MGMT levels in GS-24 
5 (d1) and a delayed decline in GS-2 (d12) (Fig. 4A). Conversely, when the M cells 25 
were returned to S conditions, they formed spheres again and accumulated MGMT 26 
15 
 
protein, with GS-2 displaying earlier protein level changes (d1) than GS-5 (d5), 1 
indicating that this effect, albeit consistent, had variable time kinetics in different 2 
model systems (Fig. 4B). MGMT regulation was directly or indirectly linked to the 3 
additional components of the NB medium since cells maintained in NB medium only 4 
did not accumulate MGMT to the extent of cells maintained in NB medium plus 5 
supplements (Fig. 4C). Cell death because of lack of supplements was excluded as a 6 
cause for lower MGMT levels (Fig. 4D).  7 
In order to assess whether a specific medium supplement was responsible for the 8 
regulation of MGMT expression in S cells, we starved GS-2 and GS-5 from individual 9 
medium supplements. We found that, while sphere formation and volume were 10 
reduced when growth factors were removed from the medium (data not shown), the 11 
levels of MGMT did not significantly vary in S cells deprived from either FGF, EGF, 12 
B27 or heparin for 3 days (Fig. 4E), a time-point where the switch to DMEM had 13 
already strongly decreased MGMT levels (Fig. 4A). Moreover, FCS deprivation did 14 
not induce MGMT in GS-5 maintained in monolayer conditions; neither did the 15 
addition of FCS alone to NB medium significantly decrease MGMT levels (Fig. 4E). 16 
Although the media supplements, either in NB medium as growth factors or in DMEM 17 
as FCS appeared to have no direct impact on MGMT expression per se, cell 18 
morphology was quite dependent on the medium in which the cells were grown (Fig. 19 
4F), and cells neither attached in DMEM without FCS nor formed spheres in NB 20 
without supplements. To finally exclude that attachment or detachment regulate 21 
MGMT expression levels, we cultured GIC sphere cells in complete NB medium for 22 
up to 6 days either with or without supplementation of 10% FCS to induce 23 
attachment. However, only a minor reduction of MGMT protein levels was observed 24 
upon attachment (Fig. 4G,H).  25 
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To exclude a sole effect of induction of attachment by FCS in this context, expression 1 
of MGMT under modulation of attachment by the integrin inhibitors cilengitide or 2 
GLPG0187 was analysed. No significant regulation of MGMT, neither on mRNA nor 3 
protein level, was observed in S or M cells exposed to either integrin inhibitor 4 
(Supplementary Fig. 2A,B). Single-cell gene expression analysis did not confirm 5 
negative correlations for expression of MGMT versus that of several adhesion 6 
molecules (Supplementary Fig. 2C). Additionally, to exclude that GIC cells under S 7 
conditions express higher levels of MGMT due to higher hypoxia levels within the 8 
spheres, driving the cells into a more stem cell state, we analysed MGMT expression 9 
levels in MGMT-expressing LTC or GIC. Intriguingly, cells kept under hypoxic 10 
conditions displayed reduced levels of MGMT on both mRNA and protein levels. 11 
Induction of hypoxia was verified by expression analysis of the hypoxia marker, 12 
carbonic anhydrase 9 (CAIX), which also confirmed higher baseline levels of hypoxia 13 
in S cultures (Supplementary Fig. 2D-F). Finally, sphere formation capacity was not 14 
impacted by silencing of MGMT or by O6-BG-mediated MGMT consumption 15 
(Supplementary Fig. 3A-C). 16 
 17 
NF-κB, a transcriptional regulator of MGMT, is overexpressed in GIC 18 
NF-κB is a transcription factor previously described to be a positive regulator of 19 
MGMT (Lavon et al., 2007). Therefore, we investigated whether NF-κB impacts 20 
MGMT regulation in human GIC cells as well. Expression of NF-κB did not differ 21 
consistently in GS-2 and GS-5 S versus M cells on mRNA levels; however, NF-κB 22 
subunit p65 protein levels were increased in S cells of GS-2 and GS-5 (Fig. 5A). 23 
Moreover, we confirmed a higher activity of NF-κB in S cells by luciferase reporter 24 
assay in GS-2 and GS-5 S versus M cells, an activity that was suppressed by pre-25 
exposure to the NF-κB inhibitor, BAY 11-7082 (Fig. 5B). Likewise, pre-exposure to 26 
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BAY 11-7082 significantly reduced MGMT protein levels in a concentration-1 
dependent manner for at least 72 h in GS-2, GS-5, T-325 and ZH-161 (Fig. 5C); in 2 
the latter cell lines, higher concentrations of the inhibitor did, however, result in cell 3 
death (data not shown), as reflected by protein degradation shown as a gradual loss 4 
of actin (Fig. 5C). Likewise, GIC exposure to moderate concentrations of BAY 11-5 
7082 over a longer period in the context of spherogenicity assays resulted in 6 
evolution of cell death after seven days, demonstrating the prosurvival function of NF-7 
κB, but precluding formal analyses of BAY 11-7082-mediated sensitization to TMZ in 8 
spherogenicity assays (data not shown). We confirmed the NF-κB-mediated 9 
regulation of MGMT by an siRNA-mediated approach using p50/p65si to silence NF-10 
κB expression (Fig. 5D). A second siRNA pool was used to validate the results in GS-11 
2, GS-5, T-325 and ZH-161 cells (Fig. 5E).  12 
 13 
MGMT expression pattern in LTC 14 
To better understand this hitherto undescribed regulation of MGMT expression, we 15 
next asked whether the differential expression of MGMT in S versus M cultures was 16 
specific to the GIC phenotype. LN-18 and T98G cells, the only MGMT-expressing 17 
LTC in our panel (Hermisson et al. 2006), formed spheres when grown in NB 18 
medium, and displayed a strong increase in MGMT levels when shifted to S 19 
conditions (Supplementary Fig. 4A,B). Similar experiments were performed as a 20 
control for two further LTC, LN-229 and LN-308, which do not express MGMT as a 21 
result of MGMT promoter methylation (Supplementary Fig. 4C). S cultures of these 22 
cells did not acquire MGMT expression (Supplementary Fig. 4D). Again, silencing of 23 
MGMT in MGMT-expressing LN-18 cells, or overexpression of MGMT in methylated 24 
LN-229 cells, did not impact their sphere formation capacity (Supplementary Fig. 25 
4E,F). LN-229 cells engineered to overexpress MGMT showed a higher level of TMZ 26 
18 
 
resistance than control cells under either conditions, although the M-to-S shift per se 1 
conferred increased TMZ resistance in the absence of MGMT induction 2 
(Supplementary Fig. 4G). 3 
 4 
5 
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Discussion 1 
 2 
The role of MGMT promoter methylation as a predictor of benefit from alkylating 3 
chemotherapy in glioblastoma is well established (Weller et al. 2010). Further, the 4 
impact of GIC for maintenance of the malignant phenotype of gliomas has been studied 5 
extensively over the last years (Lathia et al. 2015). Yet, the regulation of MGMT 6 
expression in GIC has remained poorly understood. 7 
Here, we report that GIC cultures transferred from S to M culture conditions exhibit 8 
reduced MGMT expression (Fig. 2A,B) associated with enhanced sensitivity to TMZ 9 
(Fig. 2C-E). Increased TMZ resistance in S cells was not merely linked to reduced 10 
exposure of sphere cells to TMZ, compared with M cells which grow as a flat 11 
monolayer, since there was no increase in the resistance to TMZ from M to S cells in 12 
the two cell lines lacking MGMT expression, GS-9 and ZH-305. The changes in 13 
MGMT expression in cells lacking MGMT promoter methylation could be linked 14 
neither to direct stimulating effect of a specific component of the sphere culture 15 
medium nor to a suppressive effect of FCS (Fig. 4). A relevant association of MGMT 16 
expression with cell attachment or higher MGMT expression caused by hypoxia 17 
within the spheres was excluded, too (Supplementary Fig. 2). Interestingly, the same 18 
pattern of increased MGMT protein expression was seen in 2 LTC lacking MGMT 19 
promoter methylation when grown in sphere conditions (Supplementary Fig. 4A,B). 20 
However, MGMT expression and sphere formation appear not to be directly linked, 21 
as depletion of MGMT by either gene silencing or consumption by the 22 
pharmacological inhibitor O6-BG did not result in impaired sphere formation of the 23 
cells, neither in GIC nor LTC (Supplementary Fig. 3, Supplementary Fig. 4E). In 24 
glioblastoma cells isolated from freshly resected tumor tissue and sorted for the stem 25 
cell marker CD133, increased MGMT expression was found in the CD133-positive 26 
20 
 
population (Fig. 3B) (Liu et al. 2006). Admittedly, CD133 remains a controversial 1 
stem cell marker (Beier et al. 2007); however, lacking a more reliable validated 2 
marker, sorting for CD133 remained a practicable approach for fresh tumor tissue. 3 
Moreover, a positive correlation between MGMT and common stemness markers 4 
was confirmed by single cell gene PCR, too (Fig. 3A). 5 
NF-κB, a transcription factor regulating cell survival and proliferation in several tumor 6 
entities (Naugler & Karin 2008), is also constitutively active in malignant brain tumors. 7 
It has been linked to epidermal growth factor receptor activity in glioblastoma via the 8 
PI3-kinase/Akt signalling axis (Kapoor et al. 2004), as well as to resistance to tumor 9 
necrosis factor-related apoptosis-inducing ligand-mediated apoptotic cell death 10 
(Bredel et al. 2006). Pharmacological inhibition of NF-kB was shown to induce cell 11 
death preferentially in glioblastoma cells and not in normal astrocytes (Zanotto-Filho 12 
et al. 2011). Overall, NF-kB has emerged as a focus of research for therapeutic 13 
approaches to block its downstream signalling pathway, and thus represents a 14 
potential target in tumor therapy. Several direct or indirect NF-kB inhibitors are 15 
available, such as sulfasalazine (Hermisson & Weller 2003), some of which have 16 
been used in clinical trials in chronic inflammatory disorders with clinical benefit and 17 
tolerable side effects (Combe et al. 2009). Positive effects were additionally seen for 18 
long-term outcome in patients with rheumatoid diseases, with sustained benefits of 19 
persistent disease suppression in follow-up studies after several years (van Rossum 20 
et al. 2007). A phase 1/2 prospective study using sulfasalazine in progressive WHO 21 
III or IV glioma was terminated early after the interim analysis; however, as the 22 
investigated cohort comprised 10 patients until termination, all with recurrent, large 23 
tumors and low Karnofsky performance score (median KPS: 50), those results must 24 
be interpreted with caution (Robe et al. 2009). Finally, NF-kB has been described as 25 
a regulator of MGMT expression in glioma cells (Lavon et al. 2007). In our model, we 26 
21 
 
confirmed a decrease in MGMT protein levels after inhibition of NF-kB, either by 1 
pharmacological inhibition or by a siRNA-mediated approach, therefore linking NF-kB 2 
to MGMT expression in GIC cells cultured under S conditions (Fig. 5). The NF-κB 3 
inhibitor BAY 11-7082 however induced global cell death of inhibitor-exposed cells 4 
over several days (Fig. 5C) and prohibited comparative viability assays, probably due 5 
to the utmost importance of this transcription factor for cell survival, preventing any 6 
cell growth after its complete blockage. Still, NF-kB emerges as a responsible 7 
regulator of MGMT expression in GIC S cells in our model, making this transcription 8 
factor an even more relevant putative target to therapeutic approaches, considering 9 
the indisputable relevance of stem-like cells for glioblastoma malignancy and their 10 
high resistance to therapy. 11 
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Figure legends 1 
 2 
Fig. 1. TMZ resistance of sphere cultures. A. GS-2 or GS-5 maintained as S (NB 3 
medium) or M (DMEM) (phase-contrast microscopy; size bar: 200 µm). B. mRNA 4 
expression levels of GFAP and CD133 in GS-2 or GS-5 GIC S or M were assessed 5 
by qPCR. C,D. GS-2 or GS-5 GIC grown as S or M cultures were exposed to 6 
increasing concentrations of TMZ for 24 h and allowed to grow for 2 weeks after 7 
removal of TMZ (S, white squares; M, black diamonds). Clonogenic survival was 8 
assessed by MTT assay for S and by crystal violet assay for M cultures. Data are 9 
expressed as mean ± SEM (n=3) (p<0.05, *; p<0.01, **; p<0.001, ***). E. EC50 values 10 
for GIC were determined for TMZ under S (white bars) or M (black bars) conditions 11 
(log scale) (n=3). F. Cell cycle analyses were performed by flow cytometry in GS-2 12 
and GS-5 S or M cells; cell cycle distributions are displayed as bar graphs (black, 13 
sub-G1; dark grey, G1; light grey, S; white, G2/M) (n=3). G. GS-2 and GS-5 S or M 14 
cells were seeded with 6 well replicates per time point and assessed for proliferation 15 
rates at 24 h (dark grey), 48 h (light grey) and 72 h (grey). Values were normalized to 16 
baseline for each cell lines.  17 
 18 
Fig. 2. MGMT-mediated TMZ resistance in GIC cultures. A. MGMT mRNA 19 
expression was assessed by qPCR (S, white bars; M, black bars) (n=3). B. MGMT 20 
protein levels were determined by immunoblot of lysates of S versus M cultures. β-21 
Actin was used as loading control. MGMT-negative LN-229 and MGMT-positive LN-22 
18 as well as highly MGMT-positive LN-18_R cells (Happold et al. 2012) were used 23 
as negative and positive controls (n=2). C. Correlation between the EC50 values and 24 
MGMT mRNA levels was plotted and calculated by Spearman test for S and M cells. 25 
D. GS-2 or GS-5 cells were seeded under S or M conditions, treated with 50 μM O6-26 
27 
 
BG or DMSO control for 2 h, exposed to TMZ after removal of O6-BG for 24 h at 1 
increasing concentrations, and allowed to grow for 2 weeks (S without O6-BG: white 2 
squares; S with O6-BG: grey squares; M without O6-BG: black diamonds; M with O6-3 
BG: grey diamonds) (n=3). MGMT protein levels GS-2 S cells exposed to O6-BG (50 4 
μM) or DMSO control were assessed by immunoblot after 72 h.  5 
 6 
Fig. 3. Pattern of stemness and differentiation in MGMT-expressing GIC. A. 7 
Correlations among MGMT and stem cell markers in single cell qRT-PCR analysis 8 
were determined in freshly resected glioblastoma tissues. Significant positive 9 
Pearson correlations are represented by blue ellipses. Crosses indicate non-10 
significant correlations. B. MGMT mRNA expression was assessed by qPCR in cells 11 
isolated from freshly resected tumor tissue from patients with glioblastoma; cells were 12 
sorted for presence (white bars) versus absence (black bars) of CD133 expression 13 
(n=1). C. GS-2, GS-5, T-325 or ZH-161 S cells were exposed to BMP-4 at 100 ng/ml 14 
for 72 h. MGMT protein levels were assessed by immunoblot. D. CD133 or GFAP 15 
mRNA expression were assessed by qPCR in GS-2, GS-5, T-325 or ZH-161 (without 16 
BMP-4, white bars; with BMP-4, black bars (n=2). 17 
 18 
Fig. 4. Regulation of MGMT expression by cell culture conditions. A. GS-2 or 19 
GS-5 S cells were transferred to DMEM and assessed for MGMT levels by 20 
immunoblot at the indicated time points. Respective GS S cells kept in NB medium 21 
served as control. B. GS-2 or GS-5 M were transferred to NB medium and assessed 22 
for MGMT levels by immunoblot. Respective GS M in DMEM served as control. C. 23 
GS-2 S cells were grown in either NB fully supplemented (NB-full) or pure NB 24 
medium (NB-empty) for 24, 48, 72 or 96 h, and MGMT protein levels were assessed 25 
by immunoblot. D. Viability was assessed at corresponding time points to Fig. 4C by 26 
28 
 
trypan blue exclusion assay. E. GS-5 S cells cultured in NB were transferred to NB 1 
medium deprived of (w/o) either supplement for 72 h and assessed for MGMT protein 2 
levels by immunoblot. GS-5 M cells in DMEM and GS-5 S cells in NB supplemented 3 
with 5% FCS served as a controls. F. Phase-contrast microscopy of GS-2 cells 4 
cultured in different conditions (scale 100 µm). G. GS-5 S cells were cultured in NB 5 
or NB with 5% FCS for 48 h, 96 h or 144 h, respectively. MGMT protein levels were 6 
assessed by immunoblot. H. Corresponding culture imaging (magnification 200 µm).  7 
 8 
Fig. 5. Transcriptional regulation of MGMT: a role for NF-kB. A. mRNA 9 
expression levels of NF-kB subunit p65 were assessed by qPCR for GS-2 and GS-5 10 
S and M cells. White bars, S cultures; black bars, M cultures (left panel). NF-kB 11 
subunit p65 protein levels were assessed by immunoblot in these cells (right panel). 12 
B. Luciferase reporter assays were performed in GS-2 and GS-5 S or M cells 13 
exposed to either BAY 11-7082 (15 µM) or control. Normalized luciferase expression 14 
indicates NF-kB activity. Plates were stopped 24 h after plasmid transfection and 6 h 15 
after inhibitor exposure. C. GS-2, GS-5, T-325 or ZH-161 S cells exposed to the NF-16 
kB inhibitor BAY 11-7082 at increasing concentrations as indicated or DMSO control 17 
were assessed for MGMT protein levels by immunoblot at different time points. Actin 18 
served as control. D. GS-2 or GS-5 cells were transfected either with NF-kB subunits 19 
p50/p65 siRNA or scrambled control and MGMT protein levels were assessed at 20 
different time points; gene silencing of p50/p65 was confirmed on protein levels. Actin 21 
served as control. E. The same cells as in C were transfected either with another 22 
siRNA pool for NF-kB subunits p50/p65 or scrambled control and MGMT protein 23 
levels were assessed. Actin served as control. 24 
 25 
 26 
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Supplementary Fig. 1. Stem cell and differentiation marker expression, cell death and viability in S and M cells. A. mRNA 
expression levels of CD133, Sox2, Oct4, Nanog, Musashi, Tubb3, NeuN and GFAP in GS-2 or GS-5 GIC S or M were assessed 
by qPCR (GS-2 S, white; GS-5 S, white dotted; GS-2 M, dark grey; GS-5 M, black). B. Limiting dilution assays were performed 
in GS-2, GS-5, T-325 or ZH-161 cells seeded at either 1000, 333 or 111 cells per well, and exposed to TMZ in the indicated 
concentrations. C. GS-2, GS-5, T-325 or ZH-161 cells were exposed to either DMSO control or TMZ at 100 or 1000 µM for 24 
h and allowed to grow for 10-14 days. Cell death was assessed by Annexin V/PI staining (Anx/PI -/-, white; Anx/PI +/-, dark 
grey; Anx/PI -/+, light grey; Anx/PI +/+, black).
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Supplementary Fig. 2. MGMT regulation: effects of cell adhesion and hypoxia. A, B. GS-2 cells kept under S or M 
conditions were exposed to RAD (10 µM), cilengitide (10 µM ) or GLPG0187 (1 nM). MGMT mRNA expression was 
assessed by qPCR at 24 h (A); MGMT protein levels were assessed at 24 h or 48 h by immunoblot (B). C. Correlation 
analysis was performed for MGMT and cell adhesion markers in single cell qRT-PCR analysis using freshly resected 
glioblastoma tissues. Positive Pearson correlations are represented by blue ellipses. Crosses indicate non-significant 
correlations. D. MGMT-expressing LTC (LN-18 or T98G) and GIC cells kept either under S or M conditions were 
maintained under hypoxic or normoxic conditions for 24 h, and MGMT mRNA levels were assessed by qPCR.  E. The 
same cells as in D were assessed for CAIX expression levels by qPCR. F. MGMT protein levels were assessed in LN-
18, T98G or GS-2 M by immunoblot at 24 h or 48 h under hypoxic or normoxic conditions.
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Supplementary Fig. 3. Sphere-formation capacity does not depend on MGMT expression. A. MGMT-expressing 
GS-2, GS-5 or ZH-161 S cells were transfected with MGMTsi or control. Down-regulation of MGMT protein was 
assessed by immunoblot. B. Sphere formation capacity was assessed and documented on days 5 and 10 (scale 100 
µm). C. Sphere formation capacity was assessed in the same cells after exposure to O6-BG at the same time points 
(scale 100 µm).
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Supplementary Fig. 4. MGMT regulation in sphere-forming LTC. A. MGMT-expressing LN-18 or T98G cells were 
maintained under M or switched to S conditions to promote sphere formation (scale 100 µm).  B. MGMT protein levels 
were assessed in the same cells by immunoblot. C, D. MGMT promoter-methylated LN-229 and LN-308 cells were studied 
as in A and B; LN-229_MGMT transfected cells were used as a positive control in D. E. LN-18 LTC cells expressing MGMT 
were transfected with MGMTsi or control. Sphere formation capacity was assessed and documented on days 5 and 10 
(scale 100 µm). F. LN-229_MGMT transfected cells or LN-229_NEO control-transfected cells were maintained under M or 
switched to S conditions to promote sphere formation (scale 100 µm). G. The same cells were exposed to TMZ in 
indicated concentrations and clonogenic survival was assessed by MTT assay.
